Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
BioNTech says Novartis executive Zapata-Gomez to become CFO
06:34am, Monday, 05'th May 2025
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
11:22am, Wednesday, 30'th Apr 2025
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 30'th Apr 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Wednesday, 30'th Apr 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed
09:46am, Wednesday, 30'th Apr 2025
Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investmen
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
09:38am, Wednesday, 30'th Apr 2025
In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure
Novartis to Acquire Regulus in $1.7 Billion Deal
07:50am, Wednesday, 30'th Apr 2025
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Novartis to buy Regulus Therapeutics for up to $1.7 billion
07:25am, Wednesday, 30'th Apr 2025
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceut
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
07:00am, Wednesday, 30'th Apr 2025
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximate
We have put ourselves in the right position to manage tariffs: Novartis CEO
04:05pm, Tuesday, 29'th Apr 2025
Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.
Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry
02:15pm, Tuesday, 29'th Apr 2025
Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
02:09pm, Tuesday, 29'th Apr 2025
Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Ca
Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well
12:19pm, Tuesday, 29'th Apr 2025
Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results.
Pharma firms maastraz
12:06pm, Tuesday, 29'th Apr 2025
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
